MilliporeSigma and genOway enter CRISPR collaboration

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Teka74)
(Image: Getty/Teka74)

Related tags: CRISPR, Collaboration, acquistion, Genome, Gene editing, preclinical, Preclinical contract research, Research, discovery services

genOway has acquired exclusive rights to MilliporeSigma's genome-editing patents to produce and sell new rodent models.

As per the agreement – financial details of which were not disclosed – the France-based research model developer GenOway will license MilliporeSigma’s CRISPR integration patents to develop new models that enable scientists to use CRISPR/Cas9 genome editing technology.

Additionally, GenOway will develop a network of sublicensees in model creation and distribution businesses. It also will It also will sublicense the technology for preclinical services.

The long-term research collaboration aims to develop new research tools, models, and platforms to expand MilliporeSigma’s intellectual property (IP) portfolio.

A spokesperson for MilliporeSigma told us that the alliance with genOway will enable the company to offer “custom world-class”​ animal models and services for both the pharmaceutical industry and academia.

“These models are critical components in identifying and studying physiologic and cellular targets and pathways for research and therapeutics,”​ the spokesperson explained. The disease models established per this collaboration can be used to study disease progression and pathway regulation.

Development of these models can shorten the time the industry spends testing safety and efficacy before moving to human clinical trials, the spokesperson said

Recently, Ncardia and Horizon Discovery​ entered a similar collaboration in which the companies used genetically-modified and differentiated human cells for drug discovery and preclinical models.

At the time Stefan Braam, CEO of Ncardia explained that drug delivery and development relies on pre-clinical model systems and that late-stage drug failures can be attributed to a lack of predictive pre-clinical models.

Related topics: Cell lines, Cell & Gene Therapies

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Related suppliers

Follow us

Products

View more

Webinars